Results: How CSL Limited's (ASX:CSL) profits jumped 29% this year

The CSL Limited (ASX:CSL) share price rose 2% to $205.39 following the announcement of bumper results this morning.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price rose 2% to $205.39 following the announcement of bumper results this morning. For the full year to 30 June 2018, CSL reported 15% growth in revenue to US$7.6 billion (all figures in USD) and 29% growth in net profit after tax to $1.73 billion.

This equates to diluted earnings per share of $3.81 and dividends per share of $1.72, unfranked. CSL ended the year with approximately $3.5 billion in net debt. Research development expenditure fell slightly to just below 10% of revenue, with $702 million spent on R&D in the year.

Much of the growth was driven by wider margins, with earnings before interest and tax (EBIT) margins rising from 25% to 30%. CSL's return on invested capital (ROIC) improved from 24.5% to 25.9%.

During the year CSL also delivered growth across almost every aspect of its business, with CSL Behring delivering sales growth in every region:

Source: Company presentation

Management also reported strong growth in the numbers of plasma collection centres being opened during the year. Plasma collection is a good leading indicator of growth in CSL's blood products – CSL collects the plasma to turn it into medical products for use in patients.

Recently acquired vaccine business Seqirus also delivered strong growth, growing its overall sales despite sharp falls in emerging markets and Asia Pacific:

Source: Company presentation

In its outlook for financial year 2019 (FY19) CSL guided for above-market collections growth, which means it will be attempting to grow market share in plasma collection. CSL noted that supply of plasma remains a limiting factor for the industry.

Management also guided for approximately $1.2 billion of capital expenditure as well as a ~$200 million increase in R&D expenditure to bring research spending up to 10% of revenue.

CSL has several exciting products in Phase 3 trials this year and appears set to grow for the near future.

At $200 a share it's not cheap by any measure, but I wouldn't be inclined to sell any shares.

Motley Fool contributor Sean O'Neill has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on 52-Week Highs

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
52-Week Highs

13 ASX 200 shares at 52-week highs

These shares are making their shareholders smile on Thursday.

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
52-Week Highs

These 5 ASX 200 shares just hit new 52-week highs

Do you own any of these five lucky stocks?

Read more »

ETF on white blocks with a rising arrow on top of coin piles.
52-Week Highs

12 ASX ETFs breaking the mould to hit 52-week highs today

What a day for ASX ETF investors!

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
52-Week Highs

Why is the A2 Milk share price up 46% year to date and at a 52-week high?

This infant formula company's shares have delivered the goods this year.

Read more »

Man sitting in a plane looking through a window and working on a laptop.
Travel Shares

Why is the Webjet share price racing to a 52-week high today?

Webjet has been busy talking up its WebBeds business this morning.

Read more »

Man pointing at a blue rising share price graph.
Financial Shares

Big ASX news: Macquarie share price hits new 52-week high

It's been a great day to own Macquarie shares...

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

Metcash share price hits 52-week high on broker upgrade: Time to buy?

Brokers have responded positively to its trading update.

Read more »

a woman sits amid a stylish home setting on a sofa with plush cushions with a coffee table and plant in the foreground while she peruses a tablet device.
52-Week Highs

52-week high! ASX All Ords stock surges 5% as chair steps down

Investors are shopping for Adairs shares after an announced leadership change.

Read more »